Evaluation of selected polycyclic compounds as resistance modulators in Mycobacterium tuberculosis
Loading...
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
University of the Western Cape
Abstract
Progressive development of resistance to various chemotherapeutic agents used in the management
of infectious diseases presents a serious problem in global public health. Increasing levels of
antimicrobial resistance in Mycobacterium tuberculosis (Mtb) is particularly concerning in resource
poor countries with a high incidence of tuberculosis (TB), as it is particularly difficult and very costly to
treat. The Global Tuberculosis report released by the World health Organization (WHO) in 2022 (based
on data from 2021) reports that South Africa is one of only 5 countries in the world with more than
500 cases per 100 000 people. It also falls in the WHO’s top 7 countries with the highest multidrug
resistant (MDR) TB incidence.1 The same report released in 2021 states that global TB reporting rates
dropped dramatically in 2020, and that TB death rates saw the first year-on-year increase since 2005.2
This is likely a direct consequence of COVID-19 and although improvements in reporting was seen in
2021, the trend has not yet been reversed.1 The pandemic had a negative impact on the progress made
in the fight against TB and a renewed effort is needed to achieve the goals previously set out in the
WHO End TB Strategy.
Description
Doctor Pharmaceuticae - DPharm
Keywords
Mycobacterium tuberculosis, Public health, Tuberculosis, World Health Organization (WHO), South Africa, Covid-19